Burcon NutraScience Corporation reports developments tied to plant-based protein ingredients for the food and beverage industry. Company updates cover commercialization of high-performance protein products such as Peazzaz®, FavaPro and Puratein®, production scale-up, customer adoption across beverage, nutrition and plant-based food applications, and work with manufacturing partners to support demand.
Recurring news also includes operating and financial results, convertible-debenture financing, shareholder voting matters, warrant amendments, board changes and other governance actions. Burcon's communications frequently reference its patent portfolio for proteins derived from pea, canola, soy, hemp, sunflower and other plant sources.
Burcon (OTCQB: BRCNF) announced a non-brokered private placement of unsecured convertible debentures for up to $4.0 million, with insiders committing at least $2.0 million. Each debenture is $1,000, bears 15% interest payable at maturity, matures in 48 months, and is convertible at $2.27 per share. The company may prepay or force conversion if the TSX VWAP exceeds $4.54 for 14 consecutive trading days. Proceeds will fund inventory, production capacity, general corporate purposes and repay a short-term loan. Closing is expected on or about November 28, 2025, subject to TSX approval.
Separately, Burcon drew a related-party unsecured $700,000 loan on November 7, 2025 at 12% interest with a $7,000 commitment fee; the loan matures on the earlier of four months or closing of the Offering.
Burcon (OTCQB: BRCNF) will host an investor conference call and webcast on Wednesday, November 12, 2025 at 5:00 p.m. ET to discuss fiscal 2026 second quarter results for the period ended September 30, 2025. The company said its quarterly results will be released in a press release prior to the call.
CEO Kip Underwood reiterated a calendar 2025 revenue target of $1–3 million, citing production runs committed to multiple customers and growing protein sales expected to drive revenue acceleration and margin expansion into 2026. A webcast link and archived replay are available on Burcon's website under Presentations.
Burcon (OTCQB: BRCNF) announced a University of Guelph study (Oct 20, 2025) showing Burcon's Peazazz C pea protein and Solatein sunflower protein outperformed a leading competitor's pea protein in a plant-based mozzarella-style cheese formulation.
Researchers reported superior objective texture (cold hardness, shred efficacy, melting, stretch) and sensory results (taste, aroma, color). Peazazz C and Solatein are described as >90% purity, clean-label, hypoallergenic, non-GMO proteins with neutral/mild flavor profiles suitable for dairy-alternative applications.
Burcon NutraScience (OTCQB: BRCNF), a global plant-based protein innovation leader, has appointed two new board members and announced its 2025 AGM results. Philip Dowad, a former KPMG audit partner with 43 years of experience in securities regulation, and Richard Nazur Jr., an agricultural commodity markets expert with over 20 years of experience, have joined the board.
At the AGM, all seven director nominees were successfully elected, with approval rates ranging from 71.72% to 99.45%. Shareholders also approved KPMG LLP as auditors and amended the exercise price of outstanding warrants. Mr. Dowad brings expertise in Canadian and U.S. securities requirements, while Mr. Nazur contributes extensive knowledge in global agricultural commodities trading and markets across five continents.
Burcon NutraScience (OTCQB: BRCNF) has achieved its first commercial sales of Puratein C, a high-purity canola protein isolate with over 90% protein content. The product, derived from non-GMO North American canola seeds, features a complete amino acid profile and a perfect PDCAAS score of 1.
Puratein C offers high solubility, light cream color, and mild flavor, making it suitable for various applications including dairy alternatives, beverages, meat analogues, and baked goods. This milestone represents Burcon's successful expansion into new revenue streams and demonstrates its ability to transform agricultural by-products into high-value, sustainable protein ingredients.
Burcon NutraScience (OTCQB: BRCNF) has announced the successful commercial production of Puratein®C, its high-purity canola protein isolate, at the Galesburg facility. The product, featuring over 90% protein content, is now available for immediate customer delivery.
Puratein®C is produced from non-GMO North American canola seeds and boasts a complete amino acid profile with a PDCAAS score of 1. The product's characteristics include high solubility, light cream color, and mild flavor, making it suitable for various applications including dairy alternatives, beverages, meat analogues, and nutraceuticals.
Burcon NutraScience (OTCQB: BRCNF) announced its upcoming annual general and special meeting scheduled for September 17, 2025. The company is seeking shareholder approval for a significant warrant repricing initiative to amend the exercise price of all outstanding warrants to $3.50 per Common Share.
The warrant amendments affect three tranches: 644,043 May 2023 warrants (current price $5.89), 603,094 March 2024 warrants (current price $4.544), and 297,112 Advisory warrants (current price $4.544). CEO Kip Underwood highlighted the company's commercial progress, noting over 150 active customer projects in final evaluation stages.
Due to insider holdings, the amendments require disinterested shareholder approval with separate voting for each warrant tranche, excluding votes from warrant holders and their affiliates.
Burcon NutraScience (OTCQB: BRCNF), a plant-based protein technology company, reported its fiscal 2026 Q1 results with notable progress in commercialization. The company generated revenue of $342,000, a 44% increase year-over-year, driven by initial protein sales and contract manufacturing services at its Galesburg facility.
Key achievements include securing a $6.8 million multi-year production agreement, first commercial production of Peazazz® C pea protein and FavaPro™ fava protein, and facility integration. However, the company reported a net loss of $3.5 million ($0.27 per share) and had $4.2 million in cash as of June 30, 2025. Burcon maintains its calendar 2025 revenue target of $1-3 million.
Burcon NutraScience (OTCQB: BRCNF) has announced the successful commercial production and launch of FavaPro™, a high-purity fava protein isolate containing over 90% protein content. The product, developed through Burcon's proprietary extraction process, is designed for food, beverage, and nutraceutical applications.
FavaPro™ features a neutral flavor profile and off-white color, making it suitable for various applications including dairy alternatives, nutritional beverages, snacks, and baked goods. The protein is derived from fava beans, which are nitrogen-fixing crops that improve soil health and reduce synthetic fertilizer requirements. The product received significant interest at the recent IFT FIRST tradeshow, highlighting strong market demand.
Burcon NutraScience (OTCQB: BRCNF), a global technology leader in plant-based protein innovation, has announced the appointment of Ms. Alex Varty as Interim Chief Financial Officer, effective August 4, 2025. She succeeds Mr. Robert Peets, who served as CFO since July 2024.
Ms. Varty, who joined Burcon in February 2024, brings significant experience in finance and accounting, including senior roles at KPMG LLP. She is a Chartered Professional Accountant with a Bachelor of Science in Biotechnology/Chartered Professional Accounting from the University of Waterloo. The transition comes as Burcon continues its evolution into a revenue-generating, innovation company.